The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

[View article]

To download click here

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology.

[View article]

To download click here

To download click here

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline

[View article]

To download click here

To download click here

To view the presentation click here

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive Cancer Research UK is to fund and sponsor a Phase I/II clinical trial of their SCIB2 lung cancer vaccine.

Goodfellow says the tie-up is a significant endorsement of their  ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 - which helps to prime a patient’s immune system to recognise and kill specific cancer cells.

[View interview]

To download click here